Investor presentation

RNS Number : 6849Q
Hemogenyx Pharmaceuticals PLC
08 June 2018
 

                                                             

 

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

 

Investor presentation

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it will hold a presentation for investors on Tuesday 26th June 2018.

 

The briefing by Dr. Vladislav Sandler, CEO of Hemogenyx, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Sir Marc Feldmann, Chairman

 

 

 

Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 

 

 

 

Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar

 

 

 

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey

 

 

 

Walbrook PR

Paul McManus

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

 

Mob: +44 (0)7980 541 893

     

               

 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUBVURWWANRAR
UK 100